Drugs / hyperimmune bovine colostrum
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00772590 | Mar 2009 → Mar 2010 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-09 | Immuron Ltd. | Results Uniformed Services University to Release Topline Data immuron.com.au ↗
Primary Endpoint did not reach statistical significance |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-09 | Immuron Ltd. | Uniformed Services University to Release Topline Data immuron.com.au ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hyperimmune bovine colostrum | “This study aimed to determine the effect of intensification of cART with raltegravir or addition of hyperimmune bovine colostrum (HIBC) on CD4(+) T-cell count in such patients.” PMID 21930607 ↗ Sep 2011 |
| Known as | HIBC | “This study aimed to determine the effect of intensification of cART with raltegravir or addition of hyperimmune bovine colostrum (HIBC) on CD4(+) T-cell count in such patients.” PMID 21930607 ↗ Sep 2011 |